Paper40367190
Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy.
Borges B and 21 others. Sci Transl Med, 2025. Cited by 19 papers, by iCite.
Cite this record
ConductScience Library. Intra-amniotic antisense oligonucleotide treatment improves phenotypes in preclinical models of spinal muscular atrophy. Papers, record 40367190. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40367190
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Oligonucleotides, Antisense | Major topic |
| Muscular Atrophy, Spinal | Major topic |
| Amniotic Fluid | Major topic |
| Animals | |
| Disease Models, Animal | |
| Mice | |
| Female | |
| Phenotype | |
| Motor Neurons | |
| Survival of Motor Neuron 1 Protein | |
| Pregnancy | |
| Humans | |
| Sheep |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA045508 | NCI NIH HHS | United States | P30CA045508 | PubMed and NIH | NIH RePORTER |
| R01 GM042699 | NIGMS NIH HHS | United States | R01GM042699 | PubMed and NIH | NIH RePORTER |
| R35 NS122306 | NINDS NIH HHS | United States | R35NS122306 | PubMed and NIH | NIH RePORTER |
| R37 GM042699 | NIGMS NIH HHS | United States | R01GM042699 | PubMed and NIH | NIH RePORTER |
| R37GM042699 | NIH | NIH RePORTER |
References73
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27683224 | Antisense oligonucleotides delivered to the amniotic cavity in utero modulate gene expression in the postnatal mouse. | Nucleic Acids Res | 2016 | https://conductscience.org/library/papers/27683224 | PubMed |
| 2 | 25911465 | Placental mesenchymal stromal cells rescue ambulation in ovine myelomeningocele. | Stem Cells Transl Med | 2015 | https://conductscience.org/library/papers/25911465 | PubMed |
| 3 | 39189228 | Systematic Review of Presymptomatic Treatment for Spinal Muscular Atrophy. | Int J Neonatal Screen | 2024 | https://conductscience.org/library/papers/39189228 | PubMed |
| 4 | 18371932 | Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. | Am J Hum Genet | 2008 | https://conductscience.org/library/papers/18371932 | PubMed |
| 5 | 21315257 | Early functional impairment of sensory-motor connectivity in a mouse model of spinal muscular atrophy. | Neuron | 2011 | https://conductscience.org/library/papers/21315257 | PubMed |
| 6 | 18455159 | Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. | Exp Neurol | 2008 | https://conductscience.org/library/papers/18455159 | PubMed |
| 7 | 32409122 | Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease. | Pediatr Neurol | 2020 | https://conductscience.org/library/papers/32409122 | PubMed |
| 8 | 28369979 | Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations. | J Clin Pharmacol | 2017 | https://conductscience.org/library/papers/28369979 | PubMed |
| 9 | 35715566 | Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. | Nat Med | 2022 | https://conductscience.org/library/papers/35715566 | PubMed |
| 10 | 32248834 | Longitudinal natural history of type I spinal muscular atrophy: a critical review. | Orphanet J Rare Dis | 2020 | https://conductscience.org/library/papers/32248834 | PubMed |
| 11 | 30188931 | Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice. | PLoS One | 2018 | https://conductscience.org/library/papers/30188931 | PubMed |
| 12 | 38772209 | Cognitive function in SMA patients with 2 or 3 SMN2 copies treated with SMN-modifying or gene addition therapy during the first year of life. | Eur J Paediatr Neurol | 2024 | https://conductscience.org/library/papers/38772209 | PubMed |
| 13 | 31704158 | Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. | Neuromuscul Disord | 2019 | https://conductscience.org/library/papers/31704158 | PubMed |
| 14 | 38827250 | Prenatal AAV9-GFP administration in fetal lambs results in transduction of female germ cells and maternal exposure to virus. | Mol Ther Methods Clin Dev | 2024 | https://conductscience.org/library/papers/38827250 | PubMed |
| 15 | 31124209 | Risk of miscarriage following amniocentesis or chorionic villus sampling: systematic review of literature and updated meta-analysis. | Ultrasound Obstet Gynecol | 2019 | https://conductscience.org/library/papers/31124209 | PubMed |
| 16 | 33505777 | Non-Invasive Strategies for Nose-to-Brain Drug Delivery. | J Clin Trials | 2020 | https://conductscience.org/library/papers/33505777 | PubMed |
| 17 | 33626251 | Risdiplam in Type 1 Spinal Muscular Atrophy. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33626251 | PubMed |
| 18 | 11839954 | Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. | Genet Med | 2002 | https://conductscience.org/library/papers/11839954 | PubMed |
| 19 | 12077011 | Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. | Brain | 2002 | https://conductscience.org/library/papers/12077011 | PubMed |
| 20 | 18353472 | Biomedical applications of sheep models: from asthma to vaccines. | Trends Biotechnol | 2008 | https://conductscience.org/library/papers/18353472 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 19 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42573950 | Survival Motor Neuron Protein Requirement-Supply Mismatch in Spinal Muscular Atrophy: A Conceptual Framework. | Adv Ther | 2026 | https://conductscience.org/library/papers/42573950 | PubMed |
| 42458739 | Maternal-Fetal Administration of Risdiplam Partially Rescues the SMNΔ7 Mouse Model of Spinal Muscular Atrophy. | Ann Neurol | 2026 | https://conductscience.org/library/papers/42458739 | PubMed |
| 42410005 | Using human 3D organoid models to gain mechanistic insight in motor neuron diseases. | Nat Rev Neurosci | 2026 | https://conductscience.org/library/papers/42410005 | PubMed |
| 42310398 | Ten years of disease-modifying therapy in spinal muscular atrophy: lessons learned and future directions. | Nat Rev Neurol | 2026 | https://conductscience.org/library/papers/42310398 | PubMed |
| 41660305 | Progress in RNA-Targeted Therapeutics for Human Diseases. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/41660305 | PubMed |
| 41489856 | Proband-independent noninvasive prenatal diagnosis for spinal muscular atrophy: early detection paving the way for early prenatal treatment. | Ann Med | 2026 | https://conductscience.org/library/papers/41489856 | PubMed |
| 41298837 | In utero precision medicine for severe, early-onset neurogenetic disease: scientific, clinical and ethical considerations. | Pediatr Res | 2025 | https://conductscience.org/library/papers/41298837 | PubMed |
| 41210168 | Systemic mRNA-LNP administration in fetuses improves survival in a mouse model of spinal muscular atrophy. | Mol Ther Methods Clin Dev | 2025 | https://conductscience.org/library/papers/41210168 | PubMed |
| 41137787 | Real-world evidence on nusinersen treatment of persons with SMA: a focused review. | J Neuromuscul Dis | 2026 | https://conductscience.org/library/papers/41137787 | PubMed |
| 41127529 | Chemically inducible antisense oligonucleotides for cell-specific gene silencing. | RSC Chem Biol | 2025 | https://conductscience.org/library/papers/41127529 | PubMed |
| 40906176 | Managing Spinal Muscular Atrophy: A Look at the Biology and Treatment Strategies. | Biology (Basel) | 2025 | https://conductscience.org/library/papers/40906176 | PubMed |
| 40868052 | Prenatal Management of Spinal Muscular Atrophy in the Era of Genetic Screening and Emerging Opportunities in In Utero Therapy. | Biomedicines | 2025 | https://conductscience.org/library/papers/40868052 | PubMed |
| 40802948 | Presymptomatic Treatment of a Genetic Disease with a Small-Molecule Drug. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40802948 | PubMed |
| 40731766 | Advances in Fetal Surgery: A Narrative Review of Therapeutic Interventions and Future Directions. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/40731766 | PubMed |
| 40603727 | In utero ASO therapy for spinal muscular atrophy. | Nat Rev Drug Discov | 2025 | https://conductscience.org/library/papers/40603727 | PubMed |
| 40570841 | In utero genetic therapy: Treatment of early onset neurological disorders before they start. | Mol Ther | 2025 | https://conductscience.org/library/papers/40570841 | PubMed |
| 40193572 | In utero therapy for spinal muscular atrophy: closer to clinical translation. | Brain | 2025 | https://conductscience.org/library/papers/40193572 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SMN1 | 6606 | PubTator's text mining | https://conductscience.org/library/genes/6606 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40367190
GET https://conductscience.org/api/papers/v1/40367190/authors?page=2